Literature DB >> 8452598

Infantile idiopathic myopathic carnitine deficiency: treatment with L-carnitine.

Y Shapira1, B Glick, S Harel, J J Vattin, A Gutman.   

Abstract

A series of 9 infants, ranging in age from 3 months to 5 years (average: 2 years), suffered from idiopathic myopathic carnitine deficiency presenting as hypotonia and motor delay. Secondary carnitine deficiency was eliminated by appropriate tests. Muscle carnitine concentration ranged from 2.3-7.1 nmol/mg non-collagen protein (NCP; average: 4.87 nmol/mg NCP; normal: 22 +/- 6 nmol/mg NCP). Lipid accumulation in muscle was observed in 2 of 8 patients. Therapy with L-carnitine (100 mg/kg/day in most patients) was given with clinical and laboratory follow-up 6 months later. In 7 of 9 patients, muscle tone and motor function improved. Muscle carnitine concentration increased to a range of 2.7-23.4 nmol/mg (average: 12.27 nmol/mg). In some patients the muscle carnitine content multiplied by a factor of 3-4, but carnitine concentration reached the normal range in only 2 patients. Most infants with idiopathic carnitine deficiency did benefit from 6 months of therapy; however, in order to achieve full recovery the duration of therapy should probably continue for longer periods, with a dose of not less than 100 mg/kg/day.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452598     DOI: 10.1016/0887-8994(93)90007-y

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  5 in total

Review 1.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

2.  Impaired Exercise Performance and Skeletal Muscle Mitochondrial Function in Rats with Secondary Carnitine Deficiency.

Authors:  Jamal Bouitbir; Patrizia Haegler; François Singh; Lorenz Joerin; Andrea Felser; Urs Duthaler; Stephan Krähenbühl
Journal:  Front Physiol       Date:  2016-08-10       Impact factor: 4.566

Review 3.  The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.

Authors:  Amish Chinoy; Grace R Vassallo; Emma Burkitt Wright; Judith Eelloo; Siobhan West; Eileen Hupton; Paula Galloway; Amy Pilkington; Raja Padidela; M Zulf Mughal
Journal:  J Musculoskelet Neuronal Interact       Date:  2022-03-01       Impact factor: 1.864

Review 4.  Anesthetic management of patients with carnitine deficiency or a defect of the fatty acid β-oxidation pathway: A narrative review.

Authors:  Ho Kyung Yu; Seong-Ho Ok; Sunmin Kim; Ju-Tae Sohn
Journal:  Medicine (Baltimore)       Date:  2022-02-18       Impact factor: 1.817

5.  Evaluating modified diets and dietary supplement therapies for reducing muscle lipid accumulation and improving muscle function in neurofibromatosis type 1 (NF1).

Authors:  Emily R Vasiljevski; Peter J Houweling; Thusitha Rupasinghe; Tarneet Kaur; Matthew A Summers; Ute Roessner; David G Little; Aaron Schindeler
Journal:  PLoS One       Date:  2020-08-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.